Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.
Lu JF, Rasmussen E, Karlan BY, Vergote IB, Navale L, Kuchimanchi M, Melara R, Stepan DE, Weinreich DM, Sun YN.
Cancer Chemother Pharmacol. 2012 May;69(5):1135-44. Epub 2012 Jan 1.
Related citations
Resveratrol induces SIRT1- and energy-stress-independent inhibition of tumor cell regrowth after low-dose platinum treatment.
Björklund M, Roos J, Gogvadze V, Shoshan M.
Cancer Chemother Pharmacol. 2011 Dec;68(6):1459-67. Epub 2011 Apr 11.
Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer.
Zamboni WC, Combest AJ, DeLoia JA, Edwards RP, Bridges AS, Zamboni BA, Walko CM, Yu AY, Krivak TC, Kelley JL.
Cancer Chemother Pharmacol. 2011 Nov;68(5):1255-62. Epub 2011 Mar 25.
Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin.
Kanatani I, Lin X, Yuan X, Manorek G, Shang X, Cheung LH, Rosenblum MG, Howell SB.
Cancer Chemother Pharmacol. 2011 Oct;68(4):979-90. Epub 2011 Feb 16.
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy.
Pignata S, Amant F, Scambia G, Sorio R, Breda E, Rasch W, Hernes K, Pisano C, Leunen K, Lorusso D, Cannella L, Vergote I.
Cancer Chemother Pharmacol. 2011 Nov;68(5):1347-53. Epub 2011 Sep 10.
Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells.
Wilmes A, O'Sullivan D, Chan A, Chandrahasen C, Paterson I, Northcote PT, La Flamme AC, Miller JH.
Cancer Chemother Pharmacol. 2011 Jul;68(1):117-26. Epub 2010 Sep 17.
Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study.
Muñoz-Casares FC, Rufián S, Arjona-Sánchez Á, Rubio MJ, Díaz R, Casado Á, Naranjo Á, Díaz-Iglesias CJ, Ortega R, Muñoz-Villanueva MC, Muntané J, Aranda E.
Cancer Chemother Pharmacol. 2011 Jul;68(1):267-74. Epub 2011 Apr 17.
Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect.
Garg MB, Ackland SP.
Cancer Chemother Pharmacol. 2011 Apr;67(4):963-6. Epub 2010 Oct 26.
Role of 12-lipoxygenase in regulation of ovarian cancer cell proliferation and survival.
Guo AM, Liu X, Al-Wahab Z, Maddippati KR, Ali-Fehmi R, Scicli AG, Munkarah AR.
Cancer Chemother Pharmacol. 2011 Nov;68(5):1273-83. Epub 2011 Mar 29.
A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer.
Ahmed AA, Goldsmith J, Fokt I, Le XF, Krzysko KA, Lesyng B, Bast RC Jr, Priebe W.
Cancer Chemother Pharmacol. 2011 Oct;68(4):1033-44. Epub 2011 Feb 22.
Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer.
Shah DK, Veith J, Bernacki RJ, Balthasar JP.
Cancer Chemother Pharmacol. 2011 Oct;68(4):951-8. Epub 2011 Feb 9.
Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.
Tummala R, Diegelman P, Hector S, Kramer DL, Clark K, Zagst P, Fetterly G, Porter CW, Pendyala L.
Cancer Chemother Pharmacol. 2011 Feb;67(2):401-14. Epub 2010 May 5.
Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer.
Andreopoulou E, Chen T, Liebes L, Curtin J, Blank S, Wallach R, Hochster H, Muggia F.
Cancer Chemother Pharmacol. 2011 Aug;68(2):457-63. Epub 2010 Nov 11.
Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression.
Jain D, Patel N, Shelton M, Basu A, Roque R, Siede W.
Cancer Chemother Pharmacol. 2010 Oct;66(5):945-52. Epub 2010 Jan 26.
Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts.
De Stefano I, Battaglia A, Zannoni GF, Prisco MG, Fattorossi A, Travaglia D, Baroni S, Renier D, Scambia G, Ferlini C, Gallo D.
Cancer Chemother Pharmacol. 2011 Jul;68(1):107-16. Epub 2010 Sep 17.
Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis.
Oguri T, Shimokata T, Inada M, Ito I, Ando Y, Sasaki Y, Hasegawa Y.
Cancer Chemother Pharmacol. 2010 Sep;66(4):813-7. Epub 2010 Jun 19.
Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report.
Greene DP, Ferriss JS, Jazaeri AA.
Cancer Chemother Pharmacol. 2010 Jul;66(2):265-7. Epub 2009 Oct 21.
Survival benefit from ovarian metastatectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysis.
Lee SJ, Lee J, Lim HY, Kang WK, Choi CH, Lee JW, Kim TJ, Kim BG, Bae DS, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS.
Cancer Chemother Pharmacol. 2010 Jul;66(2):229-35. Epub 2009 Oct 10.
Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane.
Feng Z, Zhao G, Yu L, Gough D, Howell SB.
Cancer Chemother Pharmacol. 2010 Apr;65(5):923-30. Epub 2009 Aug 15.
A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors.
Janjigian YY, Lee W, Kris MG, Miller VA, Krug LM, Azzoli CG, Senturk E, Calcutt MW, Rizvi NA.
Cancer Chemother Pharmacol. 2010 Apr;65(5):833-8. Epub 2009 Aug 12.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on